• DOI:10.1093/cid/ciq113
• Corpus ID: 7680788

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@article{Kelesidis2011DaptomycinNE,
  title={Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.},
  author={Theodoros Kelesidis and Romney M. Humphries and Daniel Z. Uslan and David Pegues},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2011},
  volume={52 2},
  pages={
          228-34
        }
}

• T. Kelesidis, R. Humphries, +1 author D. Pegues
• Published 15 January 2011
• Medicine, Biology
• Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA). Data on the potential emergence of daptomycin nonsusceptibility among enterococci remain limited. We systematically reviewed the published literature for reports of isolates of enterococci that were daptomycin nonsusceptible and assessed the clinical significance and outcome of therapy. Based on susceptibility breakpoints approved by the Clinical Laboratory Standards Institute (CLSI), daptomycin has in vitro activity against >90% of enterococcal isolates. Less than 2% of enterococcal isolates were daptomycin nonsusceptible, with minimum inhibitory concentrations (MICs) >4 μg/mL. The prevalence of nonsusceptibility of VRE isolates to daptomycin may be overestimated due to the spread of clonally related isolates in health care settings. Clinicians should be aware of the possibility of the emergence of daptomycin nonsusceptibility and should closely monitor daptomycin MICs of enterococci isolated during treatment.